Perhaps even more disappointingly, clinical studies evaluating combinations of mTOR and EGFR inhibitors in patients with recurrent glioma demonstrated limited responses and these were not sustained [64], [65]. The gene discussed is MTOR; the disease is central nervous system cancer.